A Phase 2 Two-Center, Randomized, Double-blind, Placebo-controlled, Paired Treatment Site Comparison Study to Evaluate the Safety and Preliminary Efficacy of a Topical Antimicrobial (NEO101) in Reduction of Wound Bioburden among Adults Treated with Curettage & Electrodessication for Superficial Basal Cell Carcinomas of the Trunk and Extremities
Latest Information Update: 16 Jul 2019
At a glance
- Drugs NEO 101 (Primary)
- Indications Basal cell cancer
- Focus Adverse reactions
- Acronyms NEO101-CLIN-BCC001
- Sponsors Neosil
- 05 Jul 2016 New trial record